MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective ß2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-373-1500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/26/2019 (Estimated)
OptionableOptionable
MediciNova (NASDAQ:MNOV) Frequently Asked Questions
What is MediciNova's stock symbol?
MediciNova trades on the NASDAQ under the ticker symbol "MNOV."
How were MediciNova's earnings last quarter?
MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.04. View MediciNova's Earnings History.
When is MediciNova's next earnings date?
What price target have analysts set for MNOV?
1 analysts have issued 12-month price targets for MediciNova's stock. Their forecasts range from $22.00 to $22.00. On average, they anticipate MediciNova's share price to reach $22.00 in the next year. This suggests a possible upside of 175.0% from the stock's current price. View Analyst Price Targets for MediciNova.
What is the consensus analysts' recommendation for MediciNova?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MediciNova.
Has MediciNova been receiving favorable news coverage?
Media coverage about MNOV stock has trended positive recently, according to InfoTrie. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MediciNova earned a news sentiment score of 2.1 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future.
Who are some of MediciNova's key competitors?
Some companies that are related to MediciNova include Aimmune Therapeutics (AIMT), Clovis Oncology (CLVS), Cambrex (CBM), Phibro Animal Health (PAHC), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), TherapeuticsMD (TXMD), Apellis Pharmaceuticals (APLS), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Epizyme (EPZM), Rhythm Pharmaceuticals (RYTM), Inflarx (IFRX), Tricida (TCDA) and Ra Pharmaceuticals (RARX).
What other stocks do shareholders of MediciNova own?
Who are MediciNova's key executives?
MediciNova's management team includes the folowing people:
- Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 69)
- Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 51)
- Dr. Kazuko Matsuda M.D., Ph.D., MPH, Chief Medical Officer (Age 53)
- Ms. Carla Reyes, Chief Financial Officer (Age 47)
- Mr. John O'Neil CPA, Controller
Who are MediciNova's major shareholders?
MediciNova's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.96%), Geode Capital Management LLC (0.99%), Geode Capital Management LLC (0.99%), D. E. Shaw & Co. Inc. (0.64%), Alps Advisors Inc. (0.23%) and FMR LLC (0.23%). Company insiders that own MediciNova stock include Yoshio Ishizaka and Yutaka Kobayashi. View Institutional Ownership Trends for MediciNova.
Which institutional investors are selling MediciNova stock?
MNOV stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, MetLife Investment Advisors LLC, Barclays PLC, California Public Employees Retirement System and Citigroup Inc.. View Insider Buying and Selling for MediciNova.
Which institutional investors are buying MediciNova stock?
MNOV stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., D. E. Shaw & Co. Inc., Bank of America Corp DE, Geode Capital Management LLC, Geode Capital Management LLC, Alps Advisors Inc., Rhumbline Advisers and Metropolitan Life Insurance Co. NY. Company insiders that have bought MediciNova stock in the last two years include Yoshio Ishizaka and Yutaka Kobayashi. View Insider Buying and Selling for MediciNova.
How do I buy shares of MediciNova?
Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MediciNova's stock price today?
One share of MNOV stock can currently be purchased for approximately $8.00.
How big of a company is MediciNova?
MediciNova has a market capitalization of $337.36 million. The biopharmaceutical company earns $-14,670,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis.
What is MediciNova's official website?
How can I contact MediciNova?
MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]
MarketBeat Community Rating for MediciNova (NASDAQ MNOV)
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
